| 9.39 0.19 (2.07%) | 05-16 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.84 | 1-year : | 13.84 |
| Resists | First : | 10.14 | Second : | 11.84 |
| Pivot price | 8.72 |
|||
| Supports | First : | 8.35 | Second : | 7.25 |
| MAs | MA(5) : | 9.36 |
MA(20) : | 8.55 |
| MA(100) : | 11.33  |
MA(250) : | 15.91 |
|
| MACD | MACD : | 0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 62.5 |
D(3) : | 66.2 |
| RSI | RSI(14): 57.6 |
|||
| 52-week | High : | 25.54 | Low : | 6.78 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ TXG ] has closed below upper band by 16.8%. Bollinger Bands are 24.8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 9.42 - 9.46 | 9.46 - 9.48 |
| Low: | 8.88 - 8.92 | 8.92 - 8.96 |
| Close: | 9.32 - 9.39 | 9.39 - 9.45 |
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Fri, 16 May 2025
'Shooting ourselves in the foot': Trump administration cuts force East Bay’s 10x Genomics into layoffs - The Business Journals
Wed, 14 May 2025
10x Genomics Wins Massive $68M Settlement Plus Royalties in Major Patent Battle with Bruker - Stock Titan
Wed, 14 May 2025
Earnings Release: Here's Why Analysts Cut Their 10x Genomics, Inc. (NASDAQ:TXG) Price Target To US$12.96 - simplywall.st
Wed, 14 May 2025
10x Genomics (TXG) Price Target Reduced by UBS Amid Funding Chal - GuruFocus
Tue, 13 May 2025
10x Genomics (TXG) Sees Price Target Lowered by UBS | TXG Stock News - GuruFocus
Tue, 13 May 2025
Canaccord Adjusts 10x Genomics (TXG) Price Target Citing Market Uncertainty | TXG Stock News - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Healthcare Information Services
|
|
| Shares Out | 109 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 1.8 (%) |
| Held by Institutions | 100.4 (%) |
| Shares Short | 12,860 (K) |
| Shares Short P.Month | 12,080 (K) |
| EPS | -1.52 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.8 |
| Profit Margin | -29.9 % |
| Operating Margin | -30.3 % |
| Return on Assets (ttm) | -12.8 % |
| Return on Equity (ttm) | -25.2 % |
| Qtrly Rev. Growth | -10.4 % |
| Gross Profit (p.s.) | 3.79 |
| Sales Per Share | 5.58 |
| EBITDA (p.s.) | -1.44 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 7 (M) |
| Levered Free Cash Flow | 60 (M) |
| PE Ratio | -6.18 |
| PEG Ratio | 0 |
| Price to Book value | 1.61 |
| Price to Sales | 1.68 |
| Price to Cash Flow | 154.21 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|